{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:33:55Z","timestamp":1775280835901,"version":"3.50.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We evaluated the influence of concomitant mineralocorticoid receptor antagonists (MRAs) on the safety and neurohumoral effects of a direct renin inhibitor in the ALiskiren Observation of Heart Failure Treatment (ALOFT) study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients with stable New York Heart Association class II\u2013IV heart failure (HF), plasma B-type natriuretic peptide (BNP) concentration &amp;gt;100 pg\/mL, and treated with an angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker) and \u03b2-blocker were randomized to once-daily, double-blind treatment with aliskiren 150 mg or placebo, added to optimal HF therapy, for 12 weeks. Safety, tolerability, and effects of aliskiren on neurohumoral biomarkers were assessed in patients who received (MRA+) and did not receive (MRA\u2212) MRA treatment at baseline. Of the 302 randomized patients, 101 were receiving MRA treatment (aliskiren, n = 52; placebo, n = 49). Mineralocorticoid receptor antagonist status did not affect the ability of aliskiren 150 mg, added to standard HF therapy, to lower BNP, N-terminal proBNP, plasma renin activity, and urinary aldosterone. For example, the end-of-study to baseline ratio of geometric mean for BNP was: MRA+ group: aliskiren 0.68 [95% confidence interval (CI) 0.47, 0.98], placebo 0.85 (0.58, 1.24); MRA\u2212 group: aliskiren 0.62 (0.45, 0.84), placebo 0.85 (0.63, 1.15), interaction P= 0.720. The incidence of pre-specified adverse events (renal dysfunction, symptomatic hypotension, and hyperkalaemia) was low, and there were no significant differences between aliskiren and placebo in either MRA subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Aliskiren 150 mg added to standard HF therapy was well tolerated over 12 weeks and provided beneficial changes in neurohumoral biomarkers regardless of concomitant MRA treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfr034","type":"journal-article","created":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T20:18:52Z","timestamp":1302034732000},"page":"755-764","source":"Crossref","is-referenced-by-count":20,"title":["Neurohumoral Effects of Aliskiren in Patients with Symptomatic Heart Failure Receiving a Mineralocorticoid Receptor Antagonist: The Aliskiren Observation of Heart Failure Treatment Study"],"prefix":"10.1093","volume":"13","author":[{"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[{"name":"University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Latini","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center , Florence ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham & Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly A.","family":"Smith","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Wright","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret F.","family":"Prescott","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"Brigham & Women's Hospital , Boston, MA ,","place":["USA"]},{"name":"British Heart Foundation Cardiovascular and Research Centre, University of Glasgow , 126 University Place, Glasgow, G12 8TA ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,2,18]]},"reference":[{"key":"2026020203303639800_ejhfhfr034-bib-0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"2026020203303639800_ejhfhfr034-bib-0002","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/eurjhf\/hfq049","article-title":"Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)","volume":"12","author":"Zannad","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026020203303639800_ejhfhfr034-bib-0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026020203303639800_ejhfhfr034-bib-0004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cardfail.2007.11.008","article-title":"Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Lakhdar","year":"2008","journal-title":"J Card Fail"},{"key":"2026020203303639800_ejhfhfr034-bib-0005","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026020203303639800_ejhfhfr034-bib-0006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/eurjhf\/hfq212","article-title":"Direct renin inhibition in addition to or as an alternative to ACE inhibition in patients with systolic chronic heart failure: rationale and design of the Aliskiren Trial to Minimize Outcomes in Patients with Heart failure (ATMOSPHERE) study","volume":"13","author":"Krum","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026020203303639800_ejhfhfr034-bib-0007","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2026020203303639800_ejhfhfr034-bib-0008","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2026020203303639800_ejhfhfr034-bib-0009","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2026020203303639800_ejhfhfr034-bib-0010","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"2026020203303639800_ejhfhfr034-bib-0011","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026020203303639800_ejhfhfr034-bib-0012","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026020203303639800_ejhfhfr034-bib-0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur Heart J"},{"key":"2026020203303639800_ejhfhfr034-bib-0014","doi-asserted-by":"crossref","first-page":"70.e23","DOI":"10.1016\/j.amjmed.2005.08.041","article-title":"Incremental prognostic value of changes in B-type natriuretic peptide in heart failure","volume":"119","author":"Latini","year":"2006","journal-title":"Am J Med"},{"key":"2026020203303639800_ejhfhfr034-bib-0015","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jacc.2008.04.069","article-title":"Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)","volume":"52","author":"Masson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026020203303639800_ejhfhfr034-bib-0016","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejheart.2007.12.006","article-title":"Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial","volume":"10","author":"Weir","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026020203303639800_ejhfhfr034-bib-0017","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jacc.2006.03.050","article-title":"Using measures of disease progression to determine therapeutic effect: a sirens' song","volume":"48","author":"Granger","year":"2006","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfr034","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfr034","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hfr034","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hfr034","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/13\/7\/755\/66469838\/eurjhf_13_7_755.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/13\/7\/755\/66469838\/eurjhf_13_7_755.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:30:44Z","timestamp":1770021044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/13\/7\/755\/8430944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,1]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,2,18]]},"published-print":{"date-parts":[[2011,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfr034","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,7]]},"published":{"date-parts":[[2011,7,1]]}}}